Reviewer's report

Title: Optimal schedule of Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer: A meta-analysis of comparative studies

Version: 1 Date: 6 March 2013

Reviewer: Salvatore siracusano

Reviewer's report:

The purpose of this meta-analysis is to evaluate the necessity of maintenance, efficacy of low-dose and superiority of various combination therapies of BCG in the treatment of superficial bladder cancer. The authors conclude patients with superficial bladder that all cancer should be encouraged to tolerate BCG maintenance with standard-dose if well tolerated and that patients can benefit from BCG combined with epirubicin or MMC but not with IFN alpha-2b.

In this context the analysis as methodologically correct should be reviewed in light of the following points:

a) at the time is not confirmed Clearly That maintenance BCG is superior as reported by Malmstrom PU Eur Urol 56: 247, 2009.

b) the problem of the dose should be analyzed according to the recent work appeared in Eur Urol in 2013 by Oddens J and Co-workers with special reference to toxicity and the cost/benefits that the treatment entails.

In conclusion, the work should be reassessed after a main revision taking into account the above suggestions.

Quality of written English: Not suitable for publication unless extensively edited

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.